Trial site
Huadong Hospital Affiliated to Fudan University
Shanghai, China 200040, ChinaNot linked to an institution yet
- 18running trials
- 8closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 25 trials
- Phase 43 trials
- Phase 2/31 trial
- Status
- Active, not recruiting9 trials
- Completed8 trials
- Recruiting6 trials
- Not yet recruiting3 trials
- Lead sponsor
- Boehringer Ingelheim4 trials
- Janssen Research & Development, LLC4 trials
- Daiichi Sankyo2 trials
- Hoffmann-La Roche2 trials
- AstraZeneca1 trial
- and 13 more
Running trials
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
NCT07627464· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Hailiang Zhang
Recruiting
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
NCT07863999· Phase 3· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Xiaoyong, Shen
Recruiting
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
NCT07272512· Phase 4· Shanghai Zhongshan Hospital· Source
Contact: Chongyi Jiang
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413· Phase 2· Shanghai Synvida Biotechnology Co.,Ltd.· Source
Contact: Jinfu Xu
Active, not recruiting
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407· AstraZeneca· Source
Not yet recruiting
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141· Beijing Friendship Hospital· Source
Contact: Yan Gu
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
NCT06531512· Phase 2/3· Oneness Biotech Co., Ltd.· Source
Active, not recruiting
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
NCT06313970· Phase 2· Fudan University· Source
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029· Peking Union Medical College Hospital· Source
Contact: Qun Cheng
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977· Phase 3· BeiGene· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error